Arbutus Biopharma Corp Presents Positive Data at AASLD 2025

By Greg Peters • Tuesday, October 07 15:33 • Permanent Link

Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced that three abstracts featuring imdusiran data and one abstract featuring ab-101 data have been accepted for poster presentations at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025, taking place in November 7–11 in Washington, DC.

The company's imdusiran therapy in patients with chronic hepatitis B virus (CHBV) was found to be safe and well tolerated when administered at both 60 mg and 90 mg dose levels every 8 weeks for 4 – 6 doses (24 – 48 weeks) and through up to 48 weeks of follow up after imdusiran dosing.

In a limited dataset, the majority of subjects who achieved hbsag response during pegylated interferon alfa-2a (IFN) treatment with or following imdusiran dosing were genotype B or C. These findings contrast with historical data from IFN therapy and suggest that imdusiran may enhance IFN responsiveness in CHBV patients with specific HBV genotypes.

The imdusiran treatment was associated with increases in soluble immune biomarkers in both im-prove I and im-prove II studies. Subjects who lost hbsag and had anti-hbs antibodies showed a greater breadth and magnitude of immune biomarker increases in im-prove I subjects compared to im-prove II.

Additionally, oral doses of ab-101 up to 30 mg qd for 28 days were generally well tolerated in NA-suppressed CHBV patients. Preliminary interim pharmacodynamic data indicate dose-related increases in PD-L1 receptor occupancy, with 83% mean maximal receptor occupancy at the 30 mg dose.

Arbutus Biopharma Corporation is currently developing imdusiran (ab-729) and an oral PD-L1 inhibitor (ab-101) for the treatment of CHBV infection. The company is also working closely with its exclusive licensee, Genevant Sciences, to protect and defend its intellectual property, which is the subject of ongoing lawsuits against Moderna and Pfizer/BioNTech for the use of Arbutus's patented LNP technology in their COVID-19 vaccines. Today the company's shares have moved -0.91% to a price of $4.34. For the full picture, make sure to review Arbutus Biopharma Corp's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.